Creatine for Depressed Male and Female Methamphetamine Users



Status:Recruiting
Conditions:Anxiety, Anxiety, Depression, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 59
Updated:4/21/2016
Start Date:November 2015
End Date:May 2017
Contact:Tracy Hellem, PhD
Email:tracy.hellem1@montana.edu
Phone:406 243 2110

Use our guide to learn which trials are right for you!

An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users

- Assess the antidepressant/anxiolytic effect of creatine in male and female
methamphetamine users

- Assess creatine's effect on methamphetamine use

- Assess the safety of creatine in male methamphetamine users with depression


Inclusion Criteria:

- Current primary diagnosis of methamphetamine dependence or abuse, with
methamphetamine preferred drug of abuse

- Current diagnosis of major depressive disorder (primary or substance-induced)

- Current diagnosis of an anxiety disorder (primary or substance-induced)

- Current Hamilton Depression Rating scale score > or = to 16

- Current Hamilton Anxiety Scale score > = to 18

- If taking a psychotropic medication for depressed or anxious mood, regimen must be
stable for > = to 4 weeks prior to creatine treatment initiation

Exclusion Criteria:

- Persons unable to provide adequate informed consent

- Persons who are at clinically significant suicidal or homicidal risk

- Primary substance-related diagnosis other than methamphetamine dependence or abuse

- Positive pregnancy test (females only)

- History of renal disease

- Clinically significant medical or neurological illness identified by history,
physical exam and laboratory testing

- History of hypersensitivity reaction to creatine
We found this trial at
1
site
Missoula, Montana 59812
Principal Investigator: Tracy Hellem, PhD
Phone: 406-243-2110
?
mi
from
Missoula, MT
Click here to add this to my saved trials